不良事件报告系统
医学
自杀意念
不利影响
利拉鲁肽
优势比
药理学
毒物控制
内科学
精神科
自杀预防
内分泌学
糖尿病
急诊医学
2型糖尿病
作者
Roger S. McIntyre,Rodrigo B. Mansur,Joshua D. Rosenblat,Angela T.H. Kwan
标识
DOI:10.1080/14740338.2023.2295397
摘要
Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide.Herein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering agents currently approved by the United States Food and Drug Administration (FDA). Reports of suicidal ideation, "depression/suicidal", suicidal behavior, suicidal attempts, and completed suicide associated with GLP-1 RA exposure reported to the FDA between 2005 and October 2023 were obtained from the FDA Adverse Event Reporting System (FAERS). We present data using the reporting odds ratio (ROR). The ROR was considered significant when the lower limit of the 95% confidence interval (CI) was greater than 1.0.Disproportionate reporting of suicidal ideation and "depression/suicidal" was observed with semaglutide and liraglutide. Disproportionate reporting of suicidal behavior, suicide attempts, and completed suicide was not observed for any of the FDA-approved GLP-1 RAs.Using the Bradford Hill criteria, however, and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.
科研通智能强力驱动
Strongly Powered by AbleSci AI